{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:37:08Z","timestamp":1792701428652,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T00:00:00Z","timestamp":1387324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.bcp.2013.12.008","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T18:16:07Z","timestamp":1387476967000},"page":"529-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":235,"title":["Tau-aggregation inhibitor therapy for Alzheimer's disease"],"prefix":"10.1016","volume":"88","author":[{"given":"Claude M.","family":"Wischik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.D.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2013.12.008_bib0005","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bcp.2012.11.014","article-title":"Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond","volume":"85","author":"Mullane","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2013.12.008_bib0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jalz.2013.03.007","article-title":"Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU\/US\/CTAD Task Force","volume":"9","author":"Vellas","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.bcp.2013.12.008_bib0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0030","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2013.12.008_bib0500","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.008_bib0045","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","article-title":"A phase II trial of huperzine A in mild to moderate Alzheimer disease","volume":"76","author":"Rafii","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.008_bib0050","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/jnnp-2012-302589","article-title":"Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans","volume":"83","author":"Maccecchini","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease","volume":"331","author":"Martone","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2013.12.008_bib0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2013.12.008_bib0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease \u2013 a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.bcp.2013.12.008_bib0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.008_bib0075","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.008_bib0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0085","series-title":"Sanofi won\u2019t chase Alzheimer's therapies, Viehbacher says. Bloomberg.com","author":"Armstrong","year":"2013"},{"key":"10.1016\/j.bcp.2013.12.008_bib0090","series-title":"137th Meeting of The American Neurological Association in Boston, Massachusetts","article-title":"Phase 3 studies of solanezumab for mild to moderate Alzheimer's disease","author":"Doody","year":"2012"},{"issue":"1","key":"10.1016\/j.bcp.2013.12.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bcp.2013.12.008_bib0100","first-page":"146","article-title":"\u00dcber eine eigenartige Erkrankung der Hirnrinde","volume":"64","author":"Alzheimer","year":"1907","journal-title":"Allg Z Psychiat Psych-Gericht Med"},{"key":"10.1016\/j.bcp.2013.12.008_bib0105","first-page":"445","article-title":"Sur les l\u00e9sions et la pathog\u00e9nie de l\u2019\u00e9pilepsie des dite essentielle","volume":"12","author":"Blocq","year":"1892","journal-title":"Sem M\u00e9d"},{"key":"10.1016\/j.bcp.2013.12.008_bib0110","first-page":"1472","article-title":"Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease","volume":"145","author":"Harrington","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","article-title":"Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease","volume":"68","author":"Fleisher","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0120","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bcp.2013.12.008_bib0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/alzrt158","article-title":"18F-florbetaben Abeta imaging in mild cognitive impairment","volume":"5","author":"Ong","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.bcp.2013.12.008_bib0130","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/197192b0","article-title":"Paired helical filaments in electron microscopy in Alzheimer's disease","volume":"197","author":"Kidd","year":"1963","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2013.12.008_bib0135","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1083\/jcb.100.6.1905","article-title":"Subunit structure of paired helical filaments in Alzheimer's disease","volume":"100","author":"Wischik","year":"1985","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/298084a0","article-title":"Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants","volume":"298","author":"Anderton","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2013.12.008_bib0145","first-page":"373","article-title":"Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class","volume":"113","author":"Yen","year":"1983","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0150","first-page":"229","article-title":"Mise en \u00e9vidence immunologique de la prot\u00e9ine tau au niveau des l\u00e9sions de d\u00e9g\u00e9n\u00e9rescence neurofibrillaire de la maladie d\u2019Alzheimer","volume":"95","author":"Brion","year":"1985","journal-title":"Arch Biol (Brux)"},{"key":"10.1016\/j.bcp.2013.12.008_bib0155","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2013.12.008_bib0160","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/j.1460-2075.1985.tb04000.x","article-title":"Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels","volume":"4","author":"Masters","year":"1985","journal-title":"EMBO J"},{"key":"10.1016\/j.bcp.2013.12.008_bib0165","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/oxfordjournals.jbchem.a135662","article-title":"Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease","volume":"99","author":"Ihara","year":"1986","journal-title":"J Biochem"},{"key":"10.1016\/j.bcp.2013.12.008_bib0170","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2013.12.008_bib0175","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","article-title":"Microtubule associated protein tau. A component of Alzheimer paired helical filaments","volume":"261","author":"Grundke-Iqbal","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.12.008_bib0180","first-page":"81","article-title":"Alzheimer's neurofibrillary tangles contain unique epitopes in common with the heat-stable microtubule-associated proteins tau and MAP2","volume":"126","author":"Yen","year":"1987","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0185","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1073\/pnas.84.9.3033","article-title":"Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains","volume":"84","author":"Perry","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2013.12.008_bib0190","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1126\/science.3029875","article-title":"Ubiquitin is a component of paired helical filaments in Alzheimer's disease","volume":"235","author":"Mori","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.bcp.2013.12.008_bib0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1899488","article-title":"A68: a major subunit of paired helical filaments and derivatized forms of normal tau","volume":"251","author":"Lee","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.bcp.2013.12.008_bib0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0896-6273(92)90117-V","article-title":"Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms","volume":"8","author":"Goedert","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2013.12.008_bib0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bcp.2013.12.008_bib0210","series-title":"Emerging drugs and targets for Alzheimer's disease. Volume 2: neuronal plasticity, neuronal protection and other miscellaneous strategies","first-page":"108","article-title":"Davunetide (NAP) pharmacology: neuroprotection and tau","author":"Gozes","year":"2010"},{"key":"10.1016\/j.bcp.2013.12.008_bib0215","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1073\/pnas.85.12.4506","article-title":"Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease","volume":"85","author":"Wischik","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2013.12.008_bib0220","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1073\/pnas.85.13.4884","article-title":"Structural characterization of the core of the paired helical filament of Alzheimer disease","volume":"85","author":"Wischik","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2013.12.008_bib0225","series-title":"Microtubule-associated proteins: modifications in disease","first-page":"185","article-title":"Modelling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development","author":"Wischik","year":"1997"},{"key":"10.1016\/j.bcp.2013.12.008_bib0230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0197-4580(95)97327-D","article-title":"Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease","volume":"16","author":"Wischik","year":"1995","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.008_bib0235","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0197-4580(95)00041-C","article-title":"Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease","volume":"16","author":"Lai","year":"1995","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.008_bib0240","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9440(10)64573-7","article-title":"Staging of cytoskeletal and \u03b2-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease","volume":"157","author":"Mukaetova-Ladinska","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0245","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1021\/bi981874p","article-title":"Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments","volume":"38","author":"Schneider","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0250","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1021\/bi400866w","article-title":"Conformational features of tau fibrils from Alzheimer's disease brain are faithfully propagated by unmodified recombinant protein","volume":"52","author":"Morozova","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0255","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2013.12.008_bib0260","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1074\/jbc.M808759200","article-title":"Propagation of tau misfolding from the outside to the inside of a cell","volume":"284","author":"Frost","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.12.008_bib0265","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0270","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bpa.12044","article-title":"Prion-like templated misfolding in tauopathies","volume":"23","author":"Clavaguera","year":"2013","journal-title":"Brain Pathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrn2786","article-title":"Prion-like mechanisms in neurodegenerative diseases","volume":"11","author":"Frost","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bcp.2013.12.008_bib0280","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0285","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.008_bib0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00401-010-0794-7","article-title":"Tau pathology in children and young adults: can you still be unconditionally baptist","volume":"121","author":"Duyckaerts","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0295","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0304-3940(93)90590-H","article-title":"Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease","volume":"162","author":"Bancher","year":"1993","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bcp.2013.12.008_bib0300","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02189115","article-title":"Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia","volume":"246","author":"Bancher","year":"1996","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.bcp.2013.12.008_bib0305","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0197-4580(97)80306-5","article-title":"Modeling the relation between neurofibrillary tangles and intellectual status","volume":"18","author":"Duyckaerts","year":"1997","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.008_bib0310","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0197-4580(99)00063-9","article-title":"Memory and mental status correlates of modified Braak staging","volume":"20","author":"Grober","year":"1999","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bcp.2013.12.008_bib0315","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/jnnp.55.3.190","article-title":"Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease","volume":"55","author":"Jobst","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0320","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1259\/bjr.75.894.750506","article-title":"Serial brain MRI at 3\u20136 month intervals as a surrogate marker for Alzheimer's disease","volume":"75","author":"Bradley","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0325","first-page":"15","article-title":"Decreased cerebral blood flow and prognosis of Alzheimer's disease: a multicenter HMPAO-SPECT study","volume":"21","author":"Nishimura","year":"2007","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.bcp.2013.12.008_bib0330","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0891-0618(01)00096-5","article-title":"Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease","volume":"22","author":"Garc\u00eda-Sierra","year":"2001","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.bcp.2013.12.008_bib0335","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0306-4522(95)90397-P","article-title":"Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes","volume":"64","author":"Ohm","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2013.12.008_bib0340","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2013.12.008_bib0345","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-010-0789-4","article-title":"The pathological process underlying Alzheimer's disease in individuals under thirty","volume":"121","author":"Braak","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0350","series-title":"PCT International Application; WO02\/055720","article-title":"Materials and methods relating to protein aggregation in neurodegenerative disease","author":"Wischik","year":"2002"},{"key":"10.1016\/j.bcp.2013.12.008_bib0355","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1021\/bi9006435","article-title":"The identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening","volume":"48","author":"Crowe","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0360","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1750-1326-1-6","article-title":"Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression","volume":"1","author":"Dickey","year":"2006","journal-title":"Mol Neurodegeneration"},{"key":"10.1016\/j.bcp.2013.12.008_bib0365","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1523\/JNEUROSCI.3345-09.2009","article-title":"Chemical manipulation of Hsp70 ATPase activity regulates tau stability","volume":"29","author":"Jinwal","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2013.12.008_bib0370","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","article-title":"Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo","volume":"8","author":"Congdon","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2013.12.008_bib0375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1750-1326-5-45","article-title":"Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden","volume":"5","author":"O\u2019Leary","year":"2010","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.bcp.2013.12.008_bib0380","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bjp.0701355","article-title":"The interaction between methylene blue and the cholinergic system","volume":"122","author":"Pfaffendorf","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0385","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0006-2952(93)90072-5","article-title":"Inhibition of nitric oxide synthesis by methylene blue","volume":"45","author":"Mayer","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0390","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1021\/bi700411k","article-title":"Methylene blue inhibits amyloid A\u03b2 oligomerization by promoting fibrillization","volume":"46","author":"Necula","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0395","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1074\/jbc.M408714200","article-title":"Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins","volume":"280","author":"Taniguchi","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2013.12.008_bib0400","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/sj.bjp.0707430","article-title":"Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction","volume":"152","author":"Ramsay","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0405","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/ALN.0b013e3181684be4","article-title":"Adverse effects of methylene blue on the central nervous system","volume":"108","author":"Vutskits","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2013.12.008_bib0410","first-page":"573","article-title":"Pharmacological evidence that methylene blue inhibits noradrenaline neuronal uptake in the rat vas deferens","volume":"55","author":"Chies","year":"2003","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-5793(97)00767-9","article-title":"Stimulation of respiration by methylene blue in rat liver mitochondria","volume":"412","author":"Visarius","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2013.12.008_bib0420","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.febslet.2009.06.042","article-title":"Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models","volume":"583","author":"Yamashita","year":"2009","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2013.12.008_bib0425","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s12031-011-9551-1","article-title":"Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43","volume":"45","author":"Mackenzie","year":"2011","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.bcp.2013.12.008_bib0430","doi-asserted-by":"crossref","first-page":"T167","DOI":"10.1016\/j.jalz.2008.05.438","article-title":"O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember\u2122 arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks","volume":"4","author":"Wischik","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.bcp.2013.12.008_bib0435","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0165-0327(83)90008-3","article-title":"Methylene blue: a possible treatment for manic depressive psychosis","volume":"5","author":"Narsapur","year":"1983","journal-title":"J Affect Disord"},{"key":"10.1016\/j.bcp.2013.12.008_bib0440","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0006-3223(88)90229-6","article-title":"Methylene blue in mania","volume":"24","author":"Naylor","year":"1988","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0445","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/0006-3223(87)90194-6","article-title":"A controlled trial of methylene blue in severe depressive psychosis","volume":"22","author":"Naylor","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bcp.2013.12.008_bib0450","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1046\/j.1471-4159.1996.67031183.x","article-title":"Polymerization of \u03c4 into filaments in the presence of heparin: the minimal sequence required for \u03c4\u2013\u03c4 interaction","volume":"67","author":"P\u00e9rez","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2013.12.008_bib0455","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0014-5793(96)01386-5","article-title":"RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments","volume":"399","author":"Kampers","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2013.12.008_bib0460","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/383550a0","article-title":"Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans","volume":"383","author":"Goedert","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2013.12.008_bib0465","series-title":"Neurobiology of Alzheimer's disease","first-page":"103","article-title":"The molecular basis of tau protein pathology in Alzheimer's disease and related neurodegenerative dementias","author":"Wischik","year":"2001"},{"key":"10.1016\/j.bcp.2013.12.008_bib0470","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tins.2011.05.006","article-title":"Clarifying lysosomal storage diseases","volume":"34","author":"Schultz","year":"2011","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bcp.2013.12.008_bib0475","doi-asserted-by":"crossref","first-page":"a006361","DOI":"10.1101\/cshperspect.a006361","article-title":"The ubiquitin\u2013proteasome system and the autophagic\u2013lysosomal system in Alzheimer disease","volume":"2","author":"Ihara","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2013.12.008_bib0480","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2013.12.008_bib0485","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2013.12.008_bib0490","first-page":"641","article-title":"Sequestration of tau by granulovacuolar degeneration in Alzheimer's disease","volume":"139","author":"Bondareff","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bcp.2013.12.008_bib0495","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1017\/S1355617702813248","article-title":"What is cognitive reserve? Theory and research application of the reserve concept","volume":"8","author":"Stern","year":"2002","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.bcp.2013.12.008_bib0505","first-page":"E313","article-title":"The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectric brush","volume":"109","author":"Wegmann","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2013.12.008_bib0510","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1002\/anie.201208290","article-title":"Mechanistic basis of phenothiazine-driven inhibition of tau aggregation","volume":"52","author":"Akoury","year":"2013","journal-title":"Angewandte Chemie Int Ed"},{"key":"10.1016\/j.bcp.2013.12.008_bib0515","doi-asserted-by":"crossref","DOI":"10.1038\/nn.3606","article-title":"Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease","author":"Khan","year":"2013","journal-title":"Nat Neurosci"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213007612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213007612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T09:16:54Z","timestamp":1647767814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295213007612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0006295213007612"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2013.12.008","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tau-aggregation inhibitor therapy for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2013.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}